An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors

This study is testing a new experimental drug, ADU-1805, to see if it is safe and effective for treating adults with advanced solid tumors. The drug works by helping your immune system better recognize and attack cancer cells, either on its own or alongside an existing immunotherapy drug.

This study is for adults over 18 with specific types of advanced solid tumors, such as lung, colon, or kidney cancer, that haven't responded to previous treatments. To join, you must be physically active enough to handle daily tasks and have healthy liver, kidney, and bone marrow function.

Participants will receive the study drug through an IV, either alone or in combination with another immunotherapy medication. Your medical team will monitor you closely with regular check-ups and scans to see how your body reacts to the treatment and how the cancer responds.

The study is currently recruiting patients at medical centers in Detroit, Michigan; St. Louis, Missouri; and Canton, Ohio. It is currently in the early phase of research, focusing on confirming safety and determining the right dosage.